glecaprevir/pibrentasivir
ApprovedSmall molecule
glecaprevir/pibrentasivir is one of 69 small molecule programs targeting Hepatitis. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
306 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Daklinza
Bristol-Myers SquibbPhase 3
Zepatier
Merck & Co.Phase 3
Pegylated Interferon
Merck & Co.Phase 3
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
TMC435
Johnson & JohnsonPhase 3
Ombitasvir/paritaprevir/ritonavir
AbbViePhase 3
Peg-Interferon Alfa-2a
Bristol-Myers SquibbPhase 3
Thymalfasin
SSciClone Pharmaceuticals
Phase 3
ABT-333
AbbViePhase 3
Peginterferon Alpha-2a
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for glecaprevir/pibrentasivir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- JJohns Hopkins University